Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Vanda Pharmaceuticals316 enrolled

Overview

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

316

Conditions

Motion Sickness

Interventions

TradipitantDRUG

Oral Capsule

PlaceboDRUG

Oral Capsule

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of motion sickness * Age 18-75 Exclusion Criteria: * Nausea-inducing disorder other than motion sickness * BMI\>40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Locations (5)

Pacific Research Partners

San Diego, California, United States

Lumos Clinical Research

San Jose, California, United States

Santa Monica Clinical Trials

Santa Monica, California, United States

Beacon Clinical Research

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Prevention of Vomiting Measured by Vomiting Assessment (VA)

Prevention of vomiting measured by Vomiting Assessment (VA) score. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited.

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.